The efficacy of PET-CT for predicting the malignant potential of gastrointestinal stromal tumors
- 11 November 2012
- journal article
- Published by Springer Science and Business Media LLC in Surgery Today
- Vol. 43 (10), 1162-1167
- https://doi.org/10.1007/s00595-012-0411-6
Abstract
Gastrointestinal stromal tumor (GIST) is the most common sarcoma of the intestinal tract. The risk category is usually determined by tumor size and mitotic count, but accurate preoperative diagnosis of GIST is very difficult. The purpose of this study is to evaluate the efficacy of positron emission tomography (PET)-CT for predicting the malignant potential of gastrointestinal stromal tumors. Ten patients with GIST who underwent a preoperative PET-CT examination were divided into two groups by risk category, and various factors were compared between the two groups. The relationships between the maximum standardized uptake value (SUVmax) and GIST parameters were examined. Patients were classified into two groups by their risk category: (low/intermediate-risk or high-risk). The SUVmax was significantly higher in the high-risk group (11.0 ± 3.04) than in the low/intermediate-risk group (2.1 ± 1.5). The Ki67 labeling index was also significantly higher in the high-risk group (8.63 ± 6.2) than in the low/intermediate-risk group (1.75 ± 0.52). There was a significant correlation between the Ki67 labeling index and the SUVmax (p = 0.028) and between the mitotic index and the SUVmax (p = 0.029). PET-CT can predict malignant potential. Cases with a SUVmax of over 5 may have malignant potential.Keywords
This publication has 26 references indexed in Scilit:
- Secondary resistance of extra-gastrointestinal stromal tumors to imatinib mesylate: Report of a caseSurgery Today, 2011
- Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033Journal of Clinical Oncology, 2008
- Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing KITJournal of Clinical Oncology, 2008
- Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST)Cancer, 2007
- Prognostic indicators for gastrointestinal stromal tumours: a clinicopathological and immunohistochemical study of 108 resected cases of the stomachHistopathology, 2003
- Malignant Gastrointestinal Stromal Tumor: Distribution, Imaging Features, and Pattern of Metastatic SpreadRadiology, 2003
- Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571)European Journal of Cancer, 2002
- Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal TumorsThe New England Journal of Medicine, 2002
- Diagnosis of gastrointestinal stromal tumors: A consensus approachHuman Pathology, 2002
- Positron emission tomography to stage suspected metastatic colorectal carcinoma to the liverThe American Journal of Surgery, 1996